OraPro-Zika - iosBio
Alternative Names: OraPro-Zika™ - iosBioLatest Information Update: 13 Jul 2022
At a glance
- Originator iosBio
- Class Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Zika virus infection
Most Recent Events
- 13 Jul 2022 ioBio plans to submit IND/CTA application for Zika virus infections (ioBio pipeline, July 2022)
- 18 Jan 2021 Preclinical trials in Zika virus infection (Prevention) in United Kingdom (PO), prior to January 2021 (iosBio pipeline, January 2021)
- 18 Jan 2021 ioBio plans phase I clinical trials in Zika virus infections (Prevention) (PO) (iosBio pipeline, January 2021)